Compare Nebius Group NV (NBIS) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nebius Group NV vs Summit Therapeutics Inc — how do they compare? Nebius Group NV trades at $218.53 (market cap $46.37B), while Summit Therapeutics Inc trades at $14.58 (market cap $10.48B). The key difference: Nebius Group NV is far larger — about 4.4× Summit Therapeutics Inc's market cap, and Nebius Group NV is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| NBIS | SMMT | |
|---|---|---|
Market Cap | $46.37B | $10.48B |
Sector | Technology | Health |
52-Week High | $286.69 | $29.32 |
52-Week Low | $50.40 | $13.05 |
Enterprise Value | $46.56B | $9.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NBIS trades at $182.62, up 2.76% today, with a bearish technical signal despite oversold RSI readings. The company reported a net income of $82.50M in 2025, with revenue of $529.80M, and shows strong projected profit margin expansion to 93.08% in 2026. Recent news highlights a significant stake increase by Nvidia, fueling positive sentiment.
Outlook is mixed: strong analyst support (88.89% buy ratings) and a $260.67 price target suggest upside, but high valuation ratios (P/E 70.51) and negative cash flow from investing pose risks. Investor focus is on execution of AI-driven growth amid competitive pressures.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
